New Consortium Aims to Develop Next-Generation Malaria Vaccine Targeting P. vivax
In a significant stride towards combating malaria, a newly formed consortium known as OptiViVax has set its sights on developing next-generation vaccines that promise increased efficacy against Plasmodium vivax (P. vivax), the most prevalent human malaria-causing pathogen. This endeavor brings together academic institutions, industry leaders, and non-profit organizations to merge cutting-edge advancements in parasite immunology,…